[1]徐淑华,郑圆花,余小燕.液基细胞学检查与高危型人乳头瘤病毒DNA检测在宫颈癌患者筛查中的临床价值[J].医学信息,2022,35(23):150-152.[doi:10.3969/j.issn.1006-1959.2022.23.032]
　XU Shu-hua,ZHENG Yuan-hua,YU Xiao-yan.The Clinical Value of Liquid-based Cytology and High-risk Human Papillomavirus DNA Detection in Cervical Cancer Screening[J].Journal of Medical Information,2022,35(23):150-152.[doi:10.3969/j.issn.1006-1959.2022.23.032]
点击复制

液基细胞学检查与高危型人乳头瘤病毒DNA检测在宫颈癌患者筛查中的临床价值()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年23期
页码:
150-152
栏目:
诊疗技术
出版日期:
2022-12-01

文章信息/Info

Title:
The Clinical Value of Liquid-based Cytology and High-risk Human Papillomavirus DNA Detection in Cervical Cancer Screening
文章编号:
1006-1959（2022）23-0150-03
作者:
徐淑华; 郑圆花; 余小燕
（1.江西中医药大学附属医院体检科，江西 南昌 330000；2.南昌市第三医院妇产科，江西 南昌 330000；3.上犹县妇幼保健院妇产科，江西 上犹 341200）
Author(s):
XU Shu-hua; ZHENG Yuan-hua; YU Xiao-yan
(1.Department of Physical Examination,Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine,Nanchang 330000,Jiangxi,China;2.Department of Obstetrics and Gynecology,the Third Hospital of Nanchang,Nanchang 330000,Jiangxi,China;3.Department of Gynecology and Obstetrics,Shangyou Maternity and Child Health Hospital,Shangyou 341200,Jiangxi,China)
关键词:
基液细胞学检测; 高危型人乳头瘤病毒; 宫颈癌
Keywords:
hinprep cytologic test; High-risk human papillomavirus; Cervical cance
分类号:
R737.33
DOI:
10.3969/j.issn.1006-1959.2022.23.032
文献标志码:
A
摘要:
目的 探讨基液细胞学检测（TCT）与高危型人乳头瘤病毒DNA检测（HPV-DNA）在宫颈癌患者筛查中的临床价值。方法 选取2020年1月-2021年9月江西中医药大学附属医院收治的宫颈癌患者120例为研究对象，以病理活检作为诊断金标准，评估TCT、HPV-DNA检测的灵敏度、特异度及诊断符合率。结果 120例宫颈标本病理学检查中炎症52例、CINⅠ级23例、CINⅡ级25例、CINⅢ级12例、宫颈癌8例，病理学结果阳性68例，阳性率为56.67%；TCT、HPV-DNA检测CINⅠ级、CINⅡ级、CINⅢ级及宫颈癌患者的阳性率高于炎症患者（P＜0.05）；TBS分类级别越高，HPV-DNA的阳性率越高（P＜0.05）；TCT联合HPV-DNA检测的灵敏度、特异度及诊断符合率均高于二者单独检测（P＜0.05）。结论 TCT和HPV-DNA的联合使用可弥补单一检测方法的不足，提高对宫颈癌或CIN诊断的灵敏度、准确度，可有效提高宫颈癌或CIN的诊断效能和筛选价值。
Abstract:
Objective To explore the clinical value of thinprep cytologic test (TCT) and high-risk human papillomavirus DNA (HPV-DNA) in cervical cancer screening.Methods A total of 120 patients with cervical cancer admitted to the Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine from January 2020 to September 2021 were selected as subjects. Pathological biopsy was used as the diagnostic gold standard to evaluate the sensitivity, specificity and diagnostic coincidence rate of TCT and HPV-DNA detection.Results Among the 120 cases of cervical specimens, there were 52 cases of inflammation, 23 cases of CINⅠ, 25 cases of CINⅡ, 12 cases of CINⅢ and 8 cases of cervical cancer. The pathological results were positive in 68 cases, with a positive rate of 56.67%. The positive rates of TCT and HPV-DNA in patients with CINⅠ, CINⅡ, CINⅢ and cervical cancer were higher than those in patients with inflammation (P<0.05). The higher the TBS classification, the higher the positive rate of HPV-DNA (P<0.05). The sensitivity, specificity and diagnostic coincidence rate of TCT combined with HPV-DNA detection were higher than those of the two alone (P<0.05).Conclusion The combined use of TCT and HPV-DNA can make up for the deficiency of single detection method, improve the sensitivity and accuracy of diagnosis of cervical cancer or CIN, and effectively improve the diagnostic efficiency and screening value of cervical cancer or CIN.

参考文献/References:

[1]Vu M,Yu J,Awolude OA,et al.Cervical cancer worldwide[J].Curr Probl Cancer,2018,42(5):457-465.[2]刘华兰.高危型人乳头瘤病毒检测联合液基薄层细胞检测在宫颈癌筛查中的价值分析[J].齐齐哈尔医学院学报,2019,40(21):2698-2699..[3]Olusola P,Banerjee HN,Philley JV,et al.Human Papilloma Virus-Associated Cervical Cancer and Health Disparities[J].Cells,2019,8(6):622.[4]陆亚玲,张金玲,许锬,等.液基薄层细胞学、高危型人乳头瘤病毒检查在宫颈癌及癌前病变筛查中的价值[J].中华疾病控制杂志,2021,25(10):1210-1213.[5]Fan Z,Feng X,Zhang W,et al.Rapid detection of high-risk HPV16 and HPV18 based on microchip electrophoresis[J].J Pharm Anal,2020,10(4):329-333.[6]廉静,张露文,陈勃同.miRNA-612表达水平对宫颈癌细胞增殖的影响[J].中国实验诊断学,2021,25(12):1762-1764.[7]赵超,赵昀,崔淑慧,等.子宫颈液基细胞学、高危型HPV及联合检测在子宫颈癌机会性筛查中的价值[J].中国妇产科临床杂志,2016,17(2):119-121.[8]王国荣,韩延霞.高危型人乳头瘤病毒16、18型感染与宫颈癌及癌前病变的相关性分析[J].中国妇幼保健,2018,33(1):67-69.[9]李婷婷,王翠峰.高危型人乳头瘤病毒联合宫颈液基薄层细胞学检测在宫颈上皮内瘤变筛查中的应用价值[J].中国全科医学,2021,24(9):1106-1110.[10]潘秦镜.TBS子宫颈细胞学报告系统回顾及新版解读[J].中国妇产科临床杂志,2017,18(1):95-96.[11]Stumbar SE,Stevens M,Feld Z.Cervical Cancer and Its Precursors: A Preventative Approach to Screening, Diagnosis, and Management[J].Prim Care,2019,46(1):117-134.[12]汪俊,王芳,田琪.TCT检测联合高危型人乳头瘤病毒早期筛查宫颈癌的价值分析[J].国际检验医学杂志,2017,38(17):2440-2442.[13]Tai YJ,Chen YY,Hsu HC,et al.Risks of cervical intraepithelial neoplasia grade 3 or invasive cancers in ASCUS women with different management: a population-based cohort study[J].J Gynecol Oncol,2018,29(4):e55.[14]晏燕,孔为民,李霞.液基薄层细胞学和高危型人乳头瘤病毒及DNA倍体分析在宫颈癌筛查中的对比分析[J].中国计划生育和妇产科,2019,11(2):66-69.[15]朱晓华,张晓兰,卢锦,等.高危型人乳头状瘤病毒配合液基薄层细胞学检查在宫颈癌早期癌前病变筛查中的应用价值分析[J].中国卫生检验杂志,2019,29(12):1502-1505.

相似文献/References:

[1]姜洪苗.高危型HPV-E6/E7mRNA检测在宫颈病变筛查中的临床价值[J].医学信息,2021,34(22):163.[doi:10.3969/j.issn.1006-1959.2021.22.050]
　JIANG Hong-miao.Clinical Value of High-risk HPV-E6/E7 mRNA Detection in Cervical Lesions Screening[J].Journal of Medical Information,2021,34(23):163.[doi:10.3969/j.issn.1006-1959.2021.22.050]

更新日期/Last Update: 1900-01-01